Pulmonary arterial hypertension in patients treated with interferon

European Respiratory Journal

Volumn 44, Issue 6, 2014, Pages 1627-1634

  Savale, Laurent ^a,b,c   Sattler, Caroline ^a,b,c   Günther, Sven ^a,b,c   Montani, David ^a,b,c   Chaumais, Marie Camille ^a,c,d   Perrin, Swanny ^a,c   Jaïs, Xavier ^a,b,c   Seferian, Andrei ^a,b,c   Jovan, Roland ^a,b,c   Bulifon, Sophie ^a,b,c   Parent, Florence ^a,b,c   Simonneau, Gérald ^a,b,c   Humbert, Marc ^a,b,c   Sitbon, Olivier ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; ANTIVIRUS AGENT; IMMUNOLOGIC FACTOR;

6 MINUTE WALK TEST; ADULT; ADVERSE OUTCOME; ARTICLE; ASCITES; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG WITHDRAWAL; ESOPHAGUS VARICES; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FEMALE; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HEART OUTPUT; HEMODYNAMIC PARAMETERS; HEMODYNAMIC STRESS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MALE; MIDDLE AGED; MIXED INFECTION; MULTIPLE SCLEROSIS; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; COHORT ANALYSIS; COINFECTION; FRANCE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; TIME;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; COINFECTION; FEMALE; FRANCE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; INTERFERON-BETA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84916241478     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00057914     Document Type: Article

References (35)

1. Rubin L. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
2. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
3. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
4. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34-D41.
5. Fishman AP. Clinical classification of pulmonary hypertension. Clin Chest Med 2001; 22: 385-391.
6. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
7. Caravita S, Secchi MB, Wu SC, et al. Sildenafil therapy for interferon-beta-1a-induced pulmonary arterial hypertension: a case report. Cardiology 2011; 120: 187-189.
8. Dhillon S, Kaker A, Dosanjh A, et al. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci 2010; 55: 1785-1790.
9. Ledinek AH, Jazbec SS, Drinovec I, et al. Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report. Mult Scler 2009; 15: 885-886.
10. Jochmann N, Kiecker F, Borges AC, et al. Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. Cardiovasc Ultrasound 2005; 3: 26.
11. Al-Zahrani H, Gupta V, Minden MD, et al. Vascular events associated with alpha interferon therapy. Leuk Lymphoma 2003; 44: 471-475.
12. Fruehauf S, Steiger S, Topaly J, et al. Pulmonary artery hypertension during interferon - a therapy for chronic myelogenous leukemia. Ann Hematol 2001; 80: 308-310.
13. Kramers C, de Mulder PH, Barth JD, et al. Acute right ventricular heart failure in a patient with renal cell carcinoma after interferon therapy. Neth J Med 1993; 42: 65-68.
14. Anderson P, Hoglund M, Rodjer S. Pulmonary side effects of interferon - a therapy in patients with hematological malignancies. Am J Hematol 2003; 73: 54-58.
15. George PM, Oliver E, Dorfmuller P, et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res 2014; 114: 677-688.
16. Woods M, Wood EG, Mitchell JA, et al. Signal transduction pathways involved in cytokine stimulation of endothelin-1 release from human vascular smooth muscle cells. J Cardiovasc Pharmacol 2000; 36: S407-S409.
17. Woods M, Wood EG, Bardswell SC, et al. Role for nuclear factor-kB and signal transducer and activator of transcription 1/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells. Mol Pharmacol 2003; 64: 923-931.
18. Badiger R, Mitchell JA, Gashaw H, et al. Effect of different interferonalpha2 preparations on IP10 and ET-1 release from human lung cells. PLoS One 2012; 7: e46779.
19. George PM, Badiger R, Alazawi W, et al. Pharmacology and therapeutic potential of interferons. Pharmacol Ther 2012; 135: 44-53.
20. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
21. Ji FP, Li ZX, Deng H, et al. Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C. World J Gastroenterol 2010; 16: 4394-4399.
22. Foster GR, Zeuzem S, Pianko S, et al. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. J Viral Hepat 2013; 20: e115-e123.
23. George PM, Cunningham ME, Galloway-Phillipps N, et al. Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ 2012; 2: 501-504.
24. Savale L, Chaumais MC, Cottin V, et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012; 40: 1164-1172.
25. Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008; 31: 343-348.
26. Rich S, Rubin L, Walker AM, et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000; 117: 870-874.
27. Assassi S, Mayes MD, Arnett FC, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 2010; 62: 589-598.
28. Black CM, Silman AJ, Herrick AI, et al. Interferon - a does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42: 299-305.
29. Eloranta ML, Franck-Larsson K, Lovgren T, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010; 69: 1396-1402.
30. Zagury D, Lachgar A, Chams V, et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998; 95: 3851-3856.
31. Lehmann C, Lafferty M, Garzino-Demo A, et al. Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients. PLoS One 2010; 5: e11110.
32. Mandl JN, Barry AP, Vanderford TH, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008; 14: 1077-1087.
33. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 8: 12-22.
34. Hanaoka M, Kubo K, Hayano T, et al. Interferon-alpha elevates pulmonary blood pressure in sheep - the role of thromboxane cascade. Eur J Pharmacol 1999; 370: 145-151.
35. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370: 222-232.